HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MLM Beautycounter Knocked By Watchdog Group For Embellishing Distributor Opportunity

Executive Summary

Truth in Advertising, Inc. (TINA.org) says it has compiled more than 100 examples of Beautycounter or its sales reps making deceptive, “atypical” income claims. The company says it paid out $120m to independent consultants in the US and Canada in 2019, but it is clear to TINA.org that “the typical Beautycounter distributor is earning little to no money.”

You may also be interested in...



Schakowsky’s Loaded Cosmetics Bill Described As ‘Floor, Not A Ceiling’ For States To Build On

The Safe Cosmetics and Personal Care Products Act, reintroduced in the US House, exceeds the proposed Personal Care Products Safety Act in the Senate in terms of the duties and resource demands it would impose on companies and the FDA, while leaving states free to regulate cosmetics even more stringently. The proposal now must vie for the attention of the Energy and Commerce Committee.

US FDA Says White Paper Could Inform Rulemaking For Cosmetic Talc-Asbestos Testing

Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.

US FDA Advises Drug Firms To Test For Benzene Contamination As Root-Cause Investigation Continues

The FDA offers insight into possible sources of benzene contamination in drug products, including aerosol spray propellants, carbomers, or other drug components made from hydrocarbons. Manufacturers that find benzene in drug product batches at levels exceeding 2 ppm should not release the product or, if already in distribution, discuss with the FDA initiating a voluntary recall.

Topics

UsernamePublicRestriction

Register

RS150256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel